v3.26.3
Collaboration Revenue - Additional Information (Details)
3 Months Ended 9 Months Ended
Sep. 30, 2026
USD ($)
Sep. 30, 2025
USD ($)
Sep. 30, 2026
USD ($)
Target
Sep. 30, 2025
USD ($)
Dec. 31, 2025
USD ($)
Research And Development Arrangement Contract To Perform For Others [Line Items]          
Research and development expense $ 30,565,000 $ 34,629,000 $ 88,372,000 $ 94,348,000  
Accounts receivable outstanding 411,000   $ 411,000   $ 0
Merck Agreement          
Research And Development Arrangement Contract To Perform For Others [Line Items]          
Number of collaboration targets | Target     2    
Non-refundable and non-creditable upfront fee     $ 8,000,000    
Payable upon selection of second collaboration target 8,000,000   8,000,000    
Milestone payments     285,000,000    
Revenue recognized 0 $ 10 0 $ 10  
Merck Agreement | Maximum          
Research And Development Arrangement Contract To Perform For Others [Line Items]          
Milestone payments per collaboration target     142,500,000    
Milestone payments upon successful completion of certain commercial milestones     350,000,000    
BMS Agreement          
Research And Development Arrangement Contract To Perform For Others [Line Items]          
Non-refundable and non-creditable upfront fee     15,000,000    
Upfront payment received     15,000,000    
Developmental milestone     35,000,000    
Revenue recognized 9,300,000   23,300,000    
Transaction price agreement initial determined amount     56,800,000    
Research and development expense     6,800,000    
Transaction price allocated for performance obligations     33,500,000    
Deferred revenue 27,300,000   27,300,000    
Deferred revenue current 27,200,000   27,200,000    
Accounts receivable outstanding $ 400,000   $ 400,000    
Remaining term of research services revenue recognized 1 year 1 month 6 days   1 year 1 month 6 days    
BMS Agreement | Maximum          
Research And Development Arrangement Contract To Perform For Others [Line Items]          
Milestone payments upon successful completion of certain commercial milestones     $ 750,000,000